Although anti-PD-1 monoclonal antibodies (mAbs) and CAR-T therapies have been actively applied in relapsed and refractory lymphoma, multiple myeloma (MM), and leukemia, which also achieved remarkable success in some cases, a part of patients still have no response to these therapies (7–10). This evidence concerns the gene PDCD1 and lymphoma.